Myeloid Leukemia | Norton Healthcare

Indication: Myeloid Leukemia

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Seattle Genetics, Inc

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.